{
    "clinical_study": {
        "@rank": "79136", 
        "brief_summary": {
            "textblock": "To evaluate the safety, tolerance, and pharmacokinetics of Retrovir (AZT) administration in\n      HIV-infected patients in renal failure receiving maintenance hemodialysis."
        }, 
        "brief_title": "Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure", 
        "condition": [
            "HIV Infections", 
            "Kidney Failure, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  A positive HIV antibody test (ELISA confirmed by Western blot).\n\n          -  Chronic renal failure managed by a stable hemodialysis regimen.\n\n          -  Acceptable hepatic function defined by specified lab values.\n\n          -  Life expectancy > 6 months.\n\n          -  Enrollment is limited to 9 chronic hemodialysis patients and 9 Continuous Ambulatory\n             Peritoneal Dialysis (CAPD) patients. These patients must be stable in their ESRD\n             treatment regimen before entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Active, serious opportunistic infections at the time of study entry.\n\n          -  Fever > 100 degrees F at study entry.\n\n          -  Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks\n             duration with = or > 6 loose stools per day accompanied by significant weight loss).\n\n        Patients with the following are excluded:\n\n          -  Active, serious opportunistic infections at the time of study entry.\n\n          -  Fever > 100 degrees F at study entry.\n\n          -  Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks\n             duration with = or > 6 loose stools per day accompanied by significant weight loss).\n\n        Prior Medication:\n\n        Excluded within 2 weeks of study entry:\n\n        - Any other experimental therapy. Drugs which cause significant bone marrow suppression.\n        Rifampin or rifampin derivatives. Cytolytic chemotherapy. Drugs which cause significant\n        hepatotoxicity.\n\n        Excluded within 4 weeks of study entry:\n\n        - Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin\n        2.\n\n        Excluded within 8 weeks of study entry:\n\n        - Other antiretroviral agents (e.g., zidovudine [AZT], suramin, ribavirin, HPA-23,\n        foscarnet, dextran sulfate, disulfiram, ddA/ddC, or dideoxycytidine).\n\n        Active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002047", 
            "org_study_id": "014H", 
            "secondary_id": "27433-19"
        }, 
        "intervention": {
            "intervention_name": "Zidovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Kidney Failure, Chronic", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine", 
            "Renal Dialysis"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21201"
                }, 
                "name": "Univ of Maryland at Baltimore"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002047"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1990"
    }, 
    "geocoordinates": {
        "Univ of Maryland at Baltimore": "39.29 -76.612"
    }
}